# Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction

Study · id `cardio:ct-nct06337175` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06337175](<https://clinicaltrials.gov/study/NCT06337175>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06337175

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 600 participants.

## Technical summary

Registry record NCT06337175. Non-randomized; no masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2023-10-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 600 participants (enrolled count; ClinicalTrials.gov record NCT06337175, source copy `cardio:ctgov-nct06337175-2025-09-05`, retrieved 2026-10-26)
- Started: 2021-06-01 (actual) (ClinicalTrials.gov record NCT06337175, source copy `cardio:ctgov-nct06337175-2025-09-05`, retrieved 2026-10-26)
- Primary completion: 2023-10-30 (actual) (ClinicalTrials.gov record NCT06337175, source copy `cardio:ctgov-nct06337175-2025-09-05`, retrieved 2026-10-26)
- Completion: 2024-04-30 (actual) (ClinicalTrials.gov record NCT06337175, source copy `cardio:ctgov-nct06337175-2025-09-05`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06337175, source copy `cardio:ctgov-nct06337175-2025-09-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06337175-2025-09-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction
- Condition: Ischemic Stroke
- Condition: Alteplase Adverse Reaction
- Intervention (Drug): Alteplase
- Intervention (Drug): Alteplase
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Alteplase (Activase) (`cardio:alteplase`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: 403f4934f27ffbe51a41dca919ef9d31eb41e4f5a1e54ab9313efaf59ad4bd32
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
